Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

738499.pdf (5.23 MB)

Document type

Article

Version

Published version

Publication date

2023-06-23

Publication license

cc-by (c) Langenmayer, Martin C. et al., 2023
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/202059

Newly designed poxviral promoters to improve immunogenicity and efficacy of MVA-NP candidate vaccine against lethal influenza virus infection in mice

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.3390/pathogens12070867

Abstract

Influenza, a respiratory disease mainly caused by influenza A and B, viruses of the Orthomyxoviridae, is still a burden on our society's health and economic system. Influenza A viruses (IAV) circulate in mammalian and avian populations, causing seasonal outbreaks with high numbers of cases. Due to the high variability in seasonal IAV triggered by antigenic drift, annual vaccination is necessary, highlighting the need for a more broadly protective vaccine against IAV. The safety tested Modified Vaccinia virus Ankara (MVA) is licensed as a third-generation vaccine against smallpox and serves as a potent vector system for the development of new candidate vaccines against different pathogens. Here, we generated and characterized recombinant MVA candidate vaccines that deliver the highly conserved internal nucleoprotein (NP) of IAV under the transcriptional control of five newly designed chimeric poxviral promoters to further increase the immunogenic properties of the recombinant viruses (MVA-NP). Infections of avian cell cultures with the recombinant MVA-NPs demonstrated efficient synthesis of the IAV-NP which was expressed under the control of the five new promoters. Prime-boost or single shot immunizations in C57BL/6 mice readily induced circulating serum antibodies' binding to recombinant IAV-NP and the robust activation of IAV-NP-specific CD8+ T cell responses. Moreover, the MVA-NP candidate vaccines protected C57BL/6 mice against lethal respiratory infection with mouse-adapted IAV (A/Puerto Rico/8/1934/H1N1). Thus, further studies are warranted to evaluate the immunogenicity and efficacy of these recombinant MVA-NP vaccines in other IAV challenge models in more detail.

Subject

Influenzavirus, Nucleoproteïnes, Vacunes, Ratolins (Animals de laboratori)

Subject (English)

Influenza viruses, Nucleoproteins, Vaccines, Mice (Laboratory animals)

Citation

Collections

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

LANGENMAYER, Martin C., et al. Newly designed poxviral promoters to improve immunogenicity and efficacy of MVA-NP candidate vaccine against lethal influenza virus infection in mice. Pathogens. 2023. Vol. 12, num. 7. ISSN 2076-0817. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/202059

Export metadata

JSON - METS

Share record